| Natural language processing systems for capturing and standardizing unstructured clinical information: a systematic review K Kreimeyer, M Foster, A Pandey, N Arya, G Halford, SF Jones, R Forshee, ... Journal of biomedical informatics 73, 14-29, 2017 | 598 | 2017 |
| A pediatric regimen for older adolescents and young adults with acute lymphoblastic leukemia: results of CALGB 10403 W Stock, SM Luger, AS Advani, J Yin, RC Harvey, CG Mullighan, ... Blood, The Journal of the American Society of Hematology 133 (14), 1548-1559, 2019 | 437 | 2019 |
| Deregulation of DUX4 and ERG in acute lymphoblastic leukemia J Zhang, K McCastlain, H Yoshihara, B Xu, Y Chang, ML Churchman, ... Nature genetics 48 (12), 1481-1489, 2016 | 323 | 2016 |
| Flotetuzumab as salvage immunotherapy for refractory acute myeloid leukemia GL Uy, I Aldoss, MC Foster, PH Sayre, MJ Wieduwilt, AS Advani, ... Blood, The Journal of the American Society of Hematology 137 (6), 751-762, 2021 | 289 | 2021 |
| A type 1 diabetes genetic risk score predicts progression of islet autoimmunity and development of type 1 diabetes in individuals at risk MJ Redondo, S Geyer, AK Steck, S Sharp, JM Wentworth, MN Weedon, ... Diabetes care 41 (9), 1887-1894, 2018 | 161 | 2018 |
| Precision medicine treatment in acute myeloid leukemia using prospective genomic profiling: feasibility and preliminary efficacy of the Beat AML Master Trial A Burd, RL Levine, AS Ruppert, AS Mims, U Borate, EM Stein, P Patel, ... Nature medicine 26 (12), 1852-1858, 2020 | 152 | 2020 |
| Favorable outcomes for older adolescents and young adults (AYA) with acute lymphoblastic leukemia (ALL): early results of US Intergroup Trial C10403 W Stock, SM Luger, AS Advani, S Geyer, RC Harvey, CG Mullighan, ... Blood 124 (21), 796, 2014 | 121 | 2014 |
| Randomized multicenter phase II study of flavopiridol (alvocidib), cytarabine, and mitoxantrone (FLAM) versus cytarabine/daunorubicin (7+ 3) in newly diagnosed acute myeloid … JF Zeidner, MC Foster, AL Blackford, MR Litzow, LE Morris, SA Strickland, ... haematologica 100 (9), 1172, 2015 | 114 | 2015 |
| Diagnostic complexities of eosinophilia ND Montgomery, CH Dunphy, M Mooberry, A Laramore, MC Foster, ... Archives of Pathology & Laboratory Medicine 137 (2), 259-269, 2013 | 83 | 2013 |
| Phase II trial of pembrolizumab after high-dose cytarabine in relapsed/refractory acute myeloid leukemia JF Zeidner, BG Vincent, A Ivanova, D Moore, KP McKinnon, AD Wilkinson, ... Blood cancer discovery 2 (6), 616-629, 2021 | 67 | 2021 |
| The effects of exercise on patient-reported outcomes and performance-based physical function in adults with acute leukemia undergoing induction therapy: exercise and quality of … AL Bryant, AM Deal, CL Battaglini, B Phillips, M Pergolotti, E Coffman, ... Integrative Cancer Therapies 17 (2), 263-270, 2018 | 67 | 2018 |
| Frontline-treatment of acute lymphoblastic leukemia (ALL) in older adolescents and young adults (AYA) using a pediatric regimen is feasible: toxicity results of the prospective … AS Advani, B Sanford, S Luger, M Devidas, EC Larsen, M Liedtke, ... Blood 122 (21), 3903, 2013 | 62 | 2013 |
| Multi-center phase 2 study of pembroluzimab (Pembro) and azacitidine (AZA) in patients with relapsed/refractory acute myeloid leukemia (AML) and in newly diagnosed (≥ 65 years … I Gojo, RK Stuart, J Webster, A Blackford, JC Varela, J Morrow, AE DeZern, ... Blood 134, 832, 2019 | 61 | 2019 |
| Preliminary results of a phase 1 study of flotetuzumab, a CD123 x CD3 bispecific Dart® protein, in patients with relapsed/refractory acute myeloid leukemia and myelodysplastic … GL Uy, J Godwin, MP Rettig, N Vey, M Foster, ML Arellano, DA Rizzieri, ... Blood 130, 637, 2017 | 61 | 2017 |
| A phase II trial of bendamustine in combination with rituximab in older patients with previously untreated diffuse large B‐cell lymphoma SI Park, NS Grover, O Olajide, AS Asch, JG Wall, KL Richards, AL Sobol, ... British journal of haematology 175 (2), 281-289, 2016 | 60 | 2016 |
| Comparison of CALGB 10403 (Alliance) and COG AALL0232 toxicity results in young adults with acute lymphoblastic leukemia AS Advani, E Larsen, K Laumann, SM Luger, M Liedtke, M Devidas, ... Blood Advances 5 (2), 504-512, 2021 | 53 | 2021 |
| Utility of a safety switch to abrogate CD19. CAR T-cell–associated neurotoxicity MC Foster, B Savoldo, W Lau, C Rubinos, N Grover, P Armistead, ... Blood, The Journal of the American Society of Hematology 137 (23), 3306-3309, 2021 | 52 | 2021 |
| Phase 1 cohort expansion of flotetuzumab, a CD123× CD3 bispecific Dart® protein in patients with relapsed/refractory acute myeloid leukemia (AML) GL Uy, MP Rettig, N Vey, J Godwin, MC Foster, DA Rizzieri, ML Arellano, ... Blood 132, 764, 2018 | 44 | 2018 |
| Final results of a randomized multicenter phase II study of alvocidib, cytarabine, and mitoxantrone versus cytarabine and daunorubicin (7+ 3) in newly diagnosed high-risk acute … JF Zeidner, MC Foster, AL Blackford, MR Litzow, LE Morris, SA Strickland, ... Leukemia research 72, 92, 2018 | 44 | 2018 |
| St. Jude Children’s Research Hospital–Washington University Pediatric Cancer Genome Project. Deregulation of DUX4 and ERG in acute lymphoblastic leukemia J Zhang, K McCastlain, H Yoshihara, B Xu, Y Chang, ML Churchman, ... Nat Genet 48 (12), 1481-1489, 2016 | 43 | 2016 |
